P R E S S
FOR IMMEDIATE RELEASE
Release Date September 28, 2026
Lanclos 1063, LLC Announces Acquisition of Revolutionary AI Weather Technology
COVINGTON, LOUISIANA — September 27, 2026 - Lanclos 1063, a Louisiana-based private investment house, announces the acquisition of SweepWX (SweepWX.com).
Louisiana is increasingly positioned to bring innovative technologies to market, and SweepWX represents another significant development in the state's growing technology landscape. “Being that our family has Louisiana roots dating back to 1720, we love Louisiana and the potential she holds, especially in technology, and we are 100% committed to supporting the entrepreneurial base here.” Said C Lanclos, CEO/Chairman of Lanclos 1063, LLC.
A New Approach to Severe Weather Detection
Lanclos became deeply interested in SweepWX after watching a real-time demonstration comparing the technology's storm analysis while tracking major weather channels. During the demonstration, SweepWX identified multiple areas of rotation that, according to Lanclos, were not detected as early or not at all by conventional tracking methods. That demonstration prompted Lanclos to become involved with the technology and its global applications.
“There's been a lot of negative news surrounding AI as of late, yet there are some very positive aspects to this technology that should not get mixed in with the negative aspects of it,” “Weather is one of those industries where technology has tremendous potential to improve how we detect and understand severe storms. With SweepWX, we plan on helping the industry move in the right direction.” said Lanclos.
Broad Applications Across Multiple Industries:
The implications of improved weather intelligence extend well beyond television forecasting. Industries including aviation, agriculture, energy, government and defense rely heavily on timely and accurate weather information. More precise observations and earlier detection of severe weather conditions could provide valuable information for organizations whose operations depend on rapidly changing atmospheric conditions.
“From aviation and agriculture to energy and defense to marine, weather affects virtually every aspect of modern life.” “The opportunity to provide earlier and more precise information about what is happening within a storm is a game changer. We know that SweepWX will contribute to a new generation of weather intelligence by combining artificial intelligence with advanced atmospheric data and real-time storm analysis." Lanclos said.
"We know that SweepWX will contribute to a new generation of weather intelligence
by combining artificial intelligence with advanced atmospheric data and
real-time storm analysis.”
C Lanclos
FOR IMMEDIATE RELEASE
Release Date October 8, 2026
Lanclos 1063, LLC Announces Investment in Groundbreaking AI Medical Imaging
COVINGTON, LOUISIANA — October 8, 2026 — Lanclos 1063, a Louisiana-based private investment house, announces an investment and partnership with AI:ON Innovations (AIONHEALTH.com), an AI-powered medical imaging architecture focused on advancing early-stage anomaly detection and institutional diagnostic safety.
Lanclos 1063 is focused on supporting innovative technologies with potential to contribute to long-term advancements in institutional markets. The firm recognizes AI:ON as an emerging development in the global healthcare imaging sector and views its technology as having potential applications across healthcare and pharmaceutical development. “We believe in supporting founders who are developing new approaches to complex challenges and building companies with long-term potential,” said C. Lanclos, CEO and Chairman of Lanclos 1063, LLC. “Our investment approach places significant emphasis on the people behind the technology—their experience, vision, and ability to translate innovation into measurable impact. We are particularly interested in opportunities where artificial intelligence can contribute to areas such as healthcare, the protection of human life, and more efficient pharmaceutical development.”
A New Approach to Medical Anomaly Detection
Lanclos 1063 became interested in AI:ON Innovations following a personal healthcare experience that highlighted the potential need for advanced AI-enabled safety and diagnostic technologies. The firm’s interest grew after reviewing the founder’s background in aerospace and defense engineering, the technology’s potential applications across healthcare, and the growing market for artificial intelligence in medical settings.
The technology’s potential was further supported by reported clinical use cases. In one case, AI:ON identified early indicators associated with an asymptomatic, rupturing gallbladder that, according to clinical reports, had not been identified during previous specialist evaluations. AI:ON’s mapping and analysis provided clinicians with additional information regarding the developing condition, contributing to the patient receiving timely medical intervention. The combination of aerospace and defense engineering expertise, AI-enabled medical analysis, and reported clinical applications led Lanclos 1063 to further engage with AI:ON Innovations and its global commercial development efforts.
“While there has been significant discussion about the risks and challenges associated with artificial intelligence, the technology is becoming an increasingly important part of our future. The focus should be on developing responsible, practical applications that can benefit society. Healthcare is an area where AI has significant potential to enhance how clinicians detect, assess, and understand serious medical conditions. With AI:ON, we see an opportunity to complement existing approaches with more advanced technology and support continued innovation in medical imaging and diagnostics,” Lanclos said.
Broad Applications Across Global Healthcare
Developed over the past decade, AI:ON’s technology was designed as a purpose-built solution rather than an off-the-shelf platform. According to company data, the technology has been deployed across more than 1,000 healthcare facilities worldwide, with reported imaging accuracy rates of 98%–99%. The platform is also designed for rapid processing. Once medical images are received from healthcare providers, the scanning and analysis process can be completed in less than five minutes, supporting integration into existing clinical workflows.
AI:ON’s intellectual property portfolio includes 178 developed solutions and patents addressing applications across more than 100 cancers and diseases, according to the company. Together, these capabilities position the technology for continued development and application across the evolving healthcare imaging market.
"With AI:ON, we believe it is time to move beyond some of the antiquated
technology that is literally thirty years old.”
C Lanclos